From: Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
Characteristic | Median or percentage | IQR |
---|---|---|
Gender (masculine) | 77.7% | Â |
Age (years) | 52 | 13 |
Risk factor for HIV | Â | Â |
Heterosexual contacts | 54.3% | Â |
Homosexual contacts | 23.4% | Â |
Intravenous drug use | 20.2% | Â |
Other | 2.1% | Â |
Number of ARV drug lines | 3 | 4 |
Time on cART (years) | 10 | 12 |
Time on current cART (months) | 37.5 | 61 |
Time below detection limit for HIV (months) | 77.5 | 61 |
Drugs in baseline ARV regimen (patients treated with drug) | Â | Â |
TDF | 52.1% | Â |
ABC | 36.2% | Â |
AZT | 3.2% | Â |
EFV | 28.7% | Â |
NVP | 13.8% | Â |
RPV | 10.6% | Â |
ETR | 4.3% | Â |
ATV/r | 13.8% | Â |
DRV/r | 12.8% | Â |
APV/r | 1.1% | Â |
LPV/r | 1.1% | Â |
RAL | 9.6% | Â |
DTG | 5.3% | Â |
EVG | 2.1% | Â |
CD4 (cells/mcL) | 673 | 403 |
Reasons for drug switch | Â | Â |
Concomitant disease | 30.9% | Â |
Abnormal laboratory test | 28.7% | Â |
Adverse Events | 19.1% | Â |
Drug/drug interaction | 13.8% | Â |
Concomitant diseases + abnormal laboratory test | 4.3% |  |
Adverse events + drug/drug interaction | 2.1% |  |
Abnormal laboratory test + drug/drug interaction | 1.1% |  |